Hoffmann Bernhard 4
4 · Ocuphire Pharma, Inc. · Filed Nov 9, 2020
Insider Transaction Report
Form 4
Hoffmann Bernhard
SVP of Corp. Dev.
Transactions
- Award
Common Stock
2020-11-05+100,120→ 100,120 total - Award
Employee Stock Option (right to buy)
2020-11-05+30,110→ 30,110 totalExercise: $1.21Exp: 2029-12-27→ Common Stock (30,110 underlying) - Award
Employee Stock Option (right to buy)
2020-11-05+42,867→ 42,867 totalExercise: $0.90Exp: 2028-10-01→ Common Stock (42,867 underlying) - Award
Employee Stock Option (right to buy)
2020-11-05+4,226→ 4,226 totalExercise: $1.65Exp: 2020-06-30→ Common Stock (4,226 underlying)
Footnotes (4)
- [F1]The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc.
- [F2]The option is fully vested.
- [F3]3,486 shares vested on December 31, 2019, and the remaining shares vest in equal monthly installments from January 2020 through December 2021, subject to continued service.
- [F4]1,373 shares vested on June 30, 2020, and the remaining shares vest in equal monthly installments from July 2020 through December 2021, subject to continued service.